GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jaguar Health Inc (HAM:1JA) » Definitions » Debt-to-EBITDA

Jaguar Health (HAM:1JA) Debt-to-EBITDA : -1.03 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Jaguar Health Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Jaguar Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €9.99 Mil. Jaguar Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €20.79 Mil. Jaguar Health's annualized EBITDA for the quarter that ended in Mar. 2024 was €-29.98 Mil. Jaguar Health's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -1.03.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Jaguar Health's Debt-to-EBITDA or its related term are showing as below:

HAM:1JA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.13   Med: -0.57   Max: -0.1
Current: -1.06

During the past 11 years, the highest Debt-to-EBITDA Ratio of Jaguar Health was -0.10. The lowest was -1.13. And the median was -0.57.

HAM:1JA's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.31 vs HAM:1JA: -1.06

Jaguar Health Debt-to-EBITDA Historical Data

The historical data trend for Jaguar Health's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jaguar Health Debt-to-EBITDA Chart

Jaguar Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.25 -0.56 -0.69 -1.04 -1.12

Jaguar Health Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.89 -0.96 -1.31 -1.10 -1.03

Competitive Comparison of Jaguar Health's Debt-to-EBITDA

For the Biotechnology subindustry, Jaguar Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jaguar Health's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jaguar Health's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Jaguar Health's Debt-to-EBITDA falls into.



Jaguar Health Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Jaguar Health's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.782 + 29.233) / -30.381
=-1.12

Jaguar Health's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(9.994 + 20.785) / -29.98
=-1.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Jaguar Health  (HAM:1JA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Jaguar Health Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Jaguar Health's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Jaguar Health (HAM:1JA) Business Description

Traded in Other Exchanges
Address
200 Pine Street, Suite 400, San Francisco, CA, USA, 94104
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments-human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Jaguar Health (HAM:1JA) Headlines

No Headlines